Kyowa Kirin Co Ltd (JP:4151)
:4151
Top Page
Kyowa Kirin Co
(4151)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥2,587.00
▲(0.06% Upside)
Action:ReiteratedDate:02/11/26
The score is driven primarily by strong financial quality—steady growth, high margins, and a very low-debt balance sheet—partly tempered by inconsistent cash flow conversion and profit margin volatility. Technicals are supportive due to price holding above major moving averages, but negative MACD limits the momentum outlook. Valuation is fair with a moderate dividend yield.
Positive Factors
Conservative balance sheet / minimal leverage
Extremely low leverage and zero reported debt in 2025 provide durable financial flexibility, lowering solvency risk and preserving optionality for R&D, licensing, or selective M&A. This conservatism supports resilience to reimbursement or product-cycle shocks over the next 2–6 months and beyond.
Negative Factors
Net margin volatility
Material swings in net margin reduce predictability of earnings and free cash generation, complicating planning for R&D, dividends, or licensing spends. If driven by mix or one-offs, volatility may persist near-term, weakening confidence in sustainable bottom-line conversion over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / minimal leverage
Extremely low leverage and zero reported debt in 2025 provide durable financial flexibility, lowering solvency risk and preserving optionality for R&D, licensing, or selective M&A. This conservatism supports resilience to reimbursement or product-cycle shocks over the next 2–6 months and beyond.
Read all positive factors
Kyowa Kirin Co (4151) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.34T
Dividend Yield2.33%
Average Volume (3M)1.20M
Price to Earnings (P/E)19.7
Beta (1Y)0.51
Revenue Growth-3.36%
EPS Growth-55.41%
CountryJP
Employees5,669
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)65.79
Shares Outstanding525,634,500
10 Day Avg. Volume1,064,410
30 Day Avg. Volume1,199,913
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)1.48
Price to Sales (P/S)2.66
P/FCF Ratio22.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,833.33Price Target Upside-29.09% Downside
Rating ConsensusStrong Sell
Number of Analyst Covering3
EPS Forecast (FY)157.03
Revenue Forecast (FY)¥521.00B
Kyowa Kirin Co Business Overview & Revenue Model
Company Description
Kyowa Kirin Co., Ltd. is a global biotechnology company based in Japan, focusing on the research, development, manufacturing, and marketing of pharmaceuticals. The company operates primarily in the fields of oncology, nephrology, and immunology, a...
How the Company Makes Money
Kyowa Kirin makes money primarily by selling prescription pharmaceuticals. Revenue is generated from (1) product sales of its marketed drugs to wholesalers, hospitals, and pharmacies (with pricing and reimbursement frameworks materially influencin...
Kyowa Kirin Co Earnings Call Summary
Earnings Call Date:Jul 31, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant growth in North American and EMEA markets, particularly in strategic products like Crysvita and Poteligeo. However, this was offset by declines in overall revenue and interim profit due to restructuring costs and challenges in the Japanese market. While there were strong performances in certain segments and promising R&D developments, the financial declines and restructuring challenges resulted in a mixed sentiment.Positive Updates
Growth in North America and EMEA
Sales in North America increased by JPY9.6 billion, or 12%, in real terms excluding forex impact. Crysvita and Poteligeo grew 11% and 15% respectively in local currency terms.
Negative Updates
Overall Revenue and Profit Decline
Revenue was JPY230.7 billion, a decrease of JPY.3 billion, or 1%. Core operating profit was JPY35 billion, a decrease of JPY9.1 billion, or 21%, and interim profit was JPY16.3 billion, a decrease of JPY21.5 billion, or 57%.
Read all updates
Q2-2025 Updates
Positive
Negative
Growth in North America and EMEA
Sales in North America increased by JPY9.6 billion, or 12%, in real terms excluding forex impact. Crysvita and Poteligeo grew 11% and 15% respectively in local currency terms.
Read all positive updates
Company Guidance
During the call, Kyowa Kirin Co., Ltd. provided financial guidance for Q2 of the fiscal year ending December 31, 2025. The company reported a revenue of JPY230.7 billion, marking a 1% decrease compared to the previous year, largely due to business restructuring in the APAC region and NHI price reductions in Japan. Core operating profit fell by 21% to JPY35 billion, attributed to a decrease in gross profit and a 7% rise in R&D expenses. Interim profit saw a significant drop of 57% to JPY16.3 billion, impacted by JPY9.4 billion in special voluntary retirement payments. Despite these declines, the company remains optimistic about achieving its full-year plan, with revenue and gross profit at 48% of the forecast and core operating profit at 44%. Sales in North America grew by 12%, driven by Crysvita and Poteligeo, which saw increases of 11% and 15%, respectively. The company is also advancing its R&D pipeline, with promising developments in products like Ziftomenib and rocatinlimab, which are undergoing crucial trials and FDA submissions.Kyowa Kirin Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 496.83B | 495.56B | 442.23B | 398.37B | 352.25B |
| Gross Profit | 356.35B | 351.22B | 320.62B | 301.36B | 253.89B |
| EBITDA | 128.42B | 116.65B | 116.94B | 100.85B | 80.61B |
| Net Income | 67.04B | 59.87B | 81.19B | 53.57B | 52.35B |
Balance Sheet | |||||
| Total Assets | 1.11T | 1.07T | 1.03T | 939.88B | 921.87B |
| Cash, Cash Equivalents and Short-Term Investments | 218.77B | 244.68B | 403.08B | 339.19B | 335.08B |
| Total Debt | 26.13B | 21.68B | 19.70B | 22.29B | 16.59B |
| Total Liabilities | 214.53B | 216.55B | 189.52B | 177.06B | 184.71B |
| Stockholders Equity | 893.33B | 850.81B | 836.42B | 762.83B | 737.16B |
Cash Flow | |||||
| Free Cash Flow | 58.90B | 41.85B | 98.34B | 33.11B | 80.03B |
| Operating Cash Flow | 96.62B | 67.88B | 115.55B | 48.67B | 86.55B |
| Investing Cash Flow | -89.19B | -142.39B | -20.38B | -17.18B | -11.36B |
| Financing Cash Flow | -36.85B | -84.70B | -32.53B | -29.03B | -28.45B |
Kyowa Kirin Co Technical Analysis
Positive
2585.50
Price Trends
2513.24
Positive
2525.95
Positive
2482.75
Positive
Market Momentum
41.38
Negative
52.18
Neutral
48.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4151, the sentiment is Positive. The current price of 2585.5 is above the 20-day moving average (MA) of 2512.63, above the 50-day MA of 2513.24, and above the 200-day MA of 2482.75, indicating a bullish trend. The MACD of 41.38 indicates Negative momentum. The RSI at 52.18 is Neutral, neither overbought nor oversold. The STOCH value of 48.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4151.
Kyowa Kirin Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥14.26T | 31.26 | 22.23% | 1.17% | 6.25% | 2.62% | |
75 Outperform | ¥4.69T | 9.34 | 7.97% | 3.61% | 13.24% | 127.88% | |
75 Outperform | ¥1.18T | 8.84 | 6.03% | 3.63% | 4.00% | -48.73% | |
72 Outperform | ¥1.34T | 19.73 | 4.27% | 2.33% | -3.36% | -55.41% | |
68 Neutral | ¥1.42T | 19.13 | 5.75% | 3.51% | 6.79% | 22.14% | |
67 Neutral | ¥5.17T | 17.88 | 18.56% | 2.07% | 12.56% | 14.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4151
Kyowa Kirin Co
2,500.00
402.32
19.18%
JP:4503
Astellas Pharma
2,560.50
1,297.81
102.78%
JP:4519
Chugai Pharmaceutical Co
8,585.00
2,188.34
34.21%
JP:4568
Daiichi Sankyo Company
2,731.50
-363.76
-11.75%
JP:4523
Eisai Co
4,946.00
1,366.63
38.18%
JP:4528
ONO Pharmaceutical Co
2,492.00
891.18
55.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.